Health CarePharmaceuticals & Biotechnology
  • Price (EUR)5.46
  • Today's Change0.01 / 0.18%
  • Shares traded9.09k
  • 1 Year change+181.59%
  • Beta5.2271
Data delayed at least 15 minutes, as of Apr 20 2021 09:41 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kiadis Pharma NV is a biopharmaceutical company based in the Netherlands. It focuses on development of therapies for patients with life-threatening diseases. Its programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. Its PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Its off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product available for a broad patient population across a potentially wide range of indications. It develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT. In addition, it has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. It has offices in the United States and Europe.

  • Revenue in EUR (TTM)17.50m
  • Net income in EUR-81.94m
  • Incorporated--
  • Employees103.00
  • Location
    Kiadis Pharma NVPaasheuvelweg 25AAMSTERDAM 1105 BPNetherlandsNLD
  • Phone+31 202405250
  • Fax+31 202405251
  • Websitehttp://www.kiadis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Oxurion NV2.08m-28.01m100.13m66.00--3.98--48.19-0.7134-0.71340.0530.65760.041910.480.824131,484.85-57.51-28.14-69.64-31.3773.5343.20-1,374.40-571.483.51--0.0419---47.34-28.6045.95---19.59--
MDxHealth SA8.97m-35.46m126.80m177.00--6.13--14.14-0.5186-0.51860.12690.18990.2405----50,670.57-95.10-40.49---------395.39-90.01---42.210.3433---58.500.1946-32.82---44.14--
Sequana Medical NV963.00k-19.11m170.90m45.00--1,287.42--177.46-1.21-1.210.0620.00720.08171.2013.61---162.17-238.47-311.11---90.86-29.21-1,984.01-1,220.842.01-15.090.9858---0.7871-10.59-27.57--9.22--
Avantium NV9.86m-22.83m172.21m218.00--3.09--17.46-0.8822-0.88220.3811.780.11851.491.0545,243.12-27.42-27.03-34.66-33.4979.8284.10-231.47-238.122.16-69.250.1735---28.64-0.79773.03--8.30--
Kiadis Pharma NV17.50m-81.94m233.77m103.00------13.36-2.14-2.140.4779-0.81670.246--6.19169,902.90-115.19-68.02-599.83-101.30-----468.23-1,121.19---0.7146---------55.68--102.68--
Acacia Pharma Group PLC175.35k-27.82m233.85m----4.18--1,333.61-0.3801-0.38010.00240.5610.0035--0.1817---55.11-78.10-66.42-190.9386.26---15,866.35-48,894.744.31-136.220.3776-------46.58------
Hyloris Pharmaceuticals SA-100.00bn-100.00bn321.62m10.00--5.34----------2.33----------------------------0.0012--0.00--4.49------
Pharming Group N.V.185.69m33.04m678.89m212.0021.554.5516.613.660.04940.04940.2720.23380.65271.306.76--11.610.047116.330.073388.9186.3517.790.07393.152.370.4689--9.8676.54-8.73--71.67--
Mithra Pharmaceuticals SA9.03m-92.09m1.13bn172.00--7.14--124.64-2.34-2.340.22993.690.01960.13380.2076---20.03-14.32-22.99-16.6761.7291.22-1,019.79-101.112.87-9.170.5432---90.64-15.07-238.28------
Data as of Apr 20 2021. Currency figures normalised to Kiadis Pharma NV's reporting currency: Euro EUR

Institutional shareholders

28.93%Per cent of shares held by top holders
HolderShares% Held
Pentwater Capital Management LPas of 18 Feb 20213.87m9.03%
UBS Asset Management Switzerland AGas of 03 Dec 20202.96m6.90%
Empery Asset Management LPas of 01 Sep 20201.95m4.55%
LSP Advisory BVas of 30 Jun 20201.52m3.53%
Carlson Capital LPas of 07 Jan 20211.22m2.84%
Norges Bank Investment Managementas of 31 Dec 2020426.09k0.99%
First Private Investment Management KAG mbHas of 30 Nov 2020133.33k0.31%
GLG Partners LPas of 16 Feb 2021118.44k0.28%
BNP Paribas Asset Management Belgium SAas of 26 Feb 2021116.93k0.27%
GAM Investment Management (Switzerland) AG (Lugano Branch)as of 26 Feb 2021100.77k0.24%
More ▼
Data from 30 Jun 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.